GlassScriptPhysician profile
Smaranda A Galis
NPI 1386611473
$2,762.78
in general payments reported to CMS, 2019-2025
34 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $158 · 2021: $220 · 2022: $382 · 2023: $213 · 2024: $13.71 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $342.18 | 2019 | |
| Sunovion Pharmaceuticals INC. | $338.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $245.64 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $222.32 | 2019-2025 | Austedo Xr |
| Abbvie INC. | $204.20 | 2021-2023 | |
| Ucb, INC. | $130.61 | 2019 | |
| Kyowa Kirin, INC. | $117.44 | 2019-2022 | |
| Argenx US, INC. | $116.38 | 2025 | Vyvgart |
| Biogen, INC. | $115.75 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $100.08 | 2022 | |
| Adamas Pharmaceuticals, INC. | $97.03 | 2019-2020 | |
| Eisai INC. | $78.71 | 2022 | |
| Allergan, INC. | $75.61 | 2019-2021 | |
| Amgen INC. | $54.85 | 2019-2023 | Aimovig |
| Genentech USA, INC. | $54.20 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.89 | 2019 | |
| Amneal Pharmaceuticals LLC | $45.98 | 2019 | |
| Lundbeck LLC | $42.58 | 2019 | |
| Neurocrine Biosciences, INC. | $41.27 | 2022-2023 | Ongentys, Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $34.00 | 2022 | |
| Celgene Corporation | $30.86 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Avion Pharmaceuticals | $24.91 | 2023 | Dhivy |
| Silk Road Medical, INC. | $22.35 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Portola Pharmaceuticals, LLC | $19.02 | 2019 | |
| Promius Pharma LLC | $18.27 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.97 | 2020 | |
| Pfizer INC. | $15.30 | 2023 | |
| Genzyme Corporation | $14.67 | 2019 | |
| Assertio Therapeutics, INC. | $14.25 | 2019 | |
| Ceribell, INC. | $14.00 | 2020 | |
| Emd Serono, INC. | $12.93 | 2019 | |
| Cala Health, INC. | $12.72 | 2023 | Cala Trio |
| Almatica Pharma LLC | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smaranda Galis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.